These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1356 related articles for article (PubMed ID: 26232605)

  • 1. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
    Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
    Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
    Taha FM; Zeeneldin AA; Helal AM; Gaber AA; Sallam YA; Ramadan H; Moneer MM
    Clin Biochem; 2009 Sep; 42(13-14):1420-6. PubMed ID: 19576877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer survival in Iranian patients.
    Aghili M; Lashkari M; Farrokhpey AH; Izadi S
    Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
    Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
    Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
    Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
    Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.